Interfering with interferons in inflammatory bowel disease
1071 - 1073
MetadataShow full item record
Early experience of fontolizumab, a humanised anti-interferon gamma antibody, in active Crohn's disease has shown that the drug caused a significant decrease in endoscopic severity scores and CRP and was reasonably well tolerated. Fontolizumab may be worthy of further clinical trials.